- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03438773
Prospective Pilot Feasibility Study Comparing Envarsus Once-a-day to Tacrolimus Twice-a-day Immunosuppressive Regimen on Drug Bioavailability in Hispanic First Time Kidney Transplant Recipients
Study Overview
Status
Intervention / Treatment
Detailed Description
Adequate drug dosing is essential to prevent allograft rejection and subsequent allograft loss. Many studies have shown that serum levels of immunosuppressant medications can be strongly influenced by the patient's genetic profile. Genetics has been shown to influence tacrolimus drug dosing in both liver and kidney transplant recipients 1. Whether these genetic differences influence care in clinical practice though is not known. Several genetic influences have been identified in Hispanic patients, such as polymorphisms in Cytochrome genes 1 and Nuclear Factor-kappa B genes 2, that might influence tacrolimus dosing and blood levels. In a study of Hispanic children, significant correlations were found to suggest that ethnic differences resulted in the need for higher or more frequent tacrolimus doing in Hispanic children 3. According to the Centers for Disease Control, Hispanics are 1.5 times as likely as non-Hispanic whites to develop ESRD 4 and Hispanics are the largest minority with the fastest growth of ESRD in the United States 5. Therefore it is likely that the unanswered question of whether there are differences in bioavailability of Envarsus in Hispanic patients will become even more relevant over time. Strategies that target improved bioavailability have the opportunity to significantly improve outcomes for all recipients of kidney transplants. Specifically, vulnerable patient populations, such as Hispanic patients, need to be studied to better understand the potential for altered bioavailability of immunosuppressive medications based on inherited pharmacologic traits.
Providing patients a once-a-day option for their immunosuppressive medication dosing is predicted to improve adherence, but whether once daily Envarsus provides adequate drug levels in Hispanic patient groups is not known. This study will carefully evaluate drug levels as a primary endpoint in this investigator-initiated study. Additional secondary outcomes to be measured over the two years of the study will be allograft rejection and allograft loss. The hypothesis of this study is that kidney transplant recipients receiving once-a-day extended release tacrolimus (Envarsus) will have outcomes that are not inferior to those who received twice-a-day tacrolimus during the two-year study period.
Study Type
Enrollment (Anticipated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Michael C Gastauer
- Phone Number: 858-810-8155
- Email: mgastauer@balboaunited.org
Study Contact Backup
- Name: Eva Gripp, LVN
- Phone Number: 858-637-4600
- Email: EGripp@balboaunited.org
Study Locations
-
-
California
-
San Diego, California, United States, 92123
- Recruiting
- California Institute of Renal Research
-
Contact:
- Eva Gripp, LVN
- Phone Number: 858-637-4600
- Email: EGripp@balboaunited.org
-
Contact:
- Karina Maldonado
- Phone Number: 858-810-8083
- Email: KMaldonado@balboaunited.org
-
Sub-Investigator:
- Steven Steinberg, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or Female 18 years of age or older.
- The subject is a first time stable renal transplant patients, who have received their transplant at least 3 months before study entry.
- The subject is willing to commit to the study design.
- The subject is considered to have stable allograft function defined as no documented rejection episodes within one month of screening.
- The subject is not currently receiving treatment with other experimental therapies directed at their transplant.
Exclusion Criteria:
- The subject has undergone a prior organ or bone marrow transplant.
- The subject has taken any interacting/contraindicated drug determined by the Investigator within 30 days of administration of the protocol.
- Any study drug allergies and if there are high serum donor specific antibody levels (DSA) or a high panel reactive antibody level (PRA).
- Documented treatment of rejection within 30 days of onset of the screening visit.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: OTHER
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
OTHER: Envarsus
Study group - Envarsus once daily in addition to standard of care.
|
Patients randomized into the Envarsus group will be prescribed Envarsus, mycophenolate and prednisone once daily.
|
OTHER: Tacrolimus
Control group - Tacrolimus twice daily in addition to standard of care.
|
Patients randomized to the Tacrolimus group will be prescribed Tacrolimus twice-daily with standard of care immunosuppression, anti-proliferative and prednisone once-daily.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Tacrolimus drug levels
Time Frame: 2 years
|
Tacrolimus trough drug levels will be studied as a primary endpoint at 24 hours after drug dosing and at steady state through local lab HPLC MS/MS assays.
|
2 years
|
Collaborators and Investigators
Investigators
- Principal Investigator: Arman Faravardeh, MD, California Institute of Renal Research
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- VLX001-17
- v01 01-Sep-2017 (OTHER: California Institute of Renal Research)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Kidney Transplant; Complications
-
University of MinnesotaWithdrawnKidney Transplant Rejection | Kidney Transplant; Complications | Kidney Transplant FailureUnited States
-
Ohio State UniversityActive, not recruitingKidney Transplant; Complications | Kidney TransplantUnited States
-
University of LiegeRecruitingKidney Transplant Rejection | Kidney Transplant; ComplicationsBelgium
-
PilloxaTerminatedLiver Transplant; Complications | Kidney Transplant; ComplicationsSweden
-
Seoul National University HospitalSamsung Medical Center; Asan Medical Center; Korea University; Yonsei University; Gachon University Gil Medical Center and other collaboratorsUnknownKidney Transplant Recipients | Complications After Kidney TransplantKorea, Republic of
-
Natera, Inc.RecruitingKidney Transplant Rejection | Kidney Transplant; Complications | Allograft RejectionUnited States
-
University of MinnesotaCompletedKidney Transplant Rejection | Kidney Transplant; Complications | Transplant; Complication, Rejection | Kidney Transplant Failure and Rejection | Transplant DysfunctionUnited States
-
Singapore General HospitalRecruitingKidney Transplant Infection | Kidney Transplant Rejection | Kidney Transplant; ComplicationsSingapore
-
Western Sydney Local Health DistrictRecruitingKidney Transplant Rejection | Kidney Transplant; ComplicationsAustralia
-
Université Catholique de LouvainUnknownImmunosuppression | Kidney Transplant; Complications | Transplant FailureBelgium
Clinical Trials on Envarsus
-
Methodist HealthcareCompletedRecipients of Liver TransplantUnited States
-
University of BrasiliaMinistry of Health, BrazilCompletedCutaneous LeishmaniasisBrazil
-
Vanderbilt University Medical CenterVeloxis PharmaceuticalsRecruitingRenal TransplantUnited States
-
Yale UniversityVeloxis PharmaceuticalsRecruitingKidney Transplant; ComplicationsUnited States
-
Veloxis PharmaceuticalsCompleted
-
Beth Israel Deaconess Medical CenterVeloxis PharmaceuticalsNot yet recruitingMedication Adherence | Renal Transplant
-
Universitätsklinikum Hamburg-EppendorfCompletedLiver TransplantationGermany
-
Sentara Norfolk General HospitalVeloxis PharmaceuticalsCompletedTransplant;Failure,KidneyUnited States
-
Baylor Research InstituteActive, not recruitingCompliance, Patient | Graft Failure | Heart Transplant RejectionUnited States
-
University of Colorado, DenverCompleted